Peppy vs. Amino USA: what a research COA can establish

Disclosure: Peppy Care publishes this comparison of its own service. Public information checked October 22, 2026; no firsthand product testing. Seller statements are attributed, not independently certified.

A search-indexed excerpt of an Amino USA GHK-Cu report describes analytical testing and limits results to submitted samples. It also states research-use restrictions. Direct access to the site and complete PDF was blocked during this review, so this article relies only on that indexed excerpt for those observations.

We did not authenticate the report, inspect its full methods, verify any purity number, or confirm current inventory. These limits are part of the comparison, not evidence of wrongdoing. A search engine can retain a document excerpt when a reviewer cannot open the source, and that excerpt can omit important context.

An analytical document should be connected to the material it describes. The report identifier, sample description, testing date, and batch relationship help define that connection. A document for one submitted sample does not automatically describe every item sold under a brand name.

Different tests answer different questions. An identity result is not the same as a measurement of quantity, and neither by itself demonstrates a clinical benefit. Without the complete report, it is especially inappropriate to fill those gaps from the product’s title. Our COA reading guide explains how to distinguish a reported result from an inference the document does not support.

A decision about treating a person starts with the medical problem, relevant history, and available options. It also requires an exact proposed medicine, an explanation of likely benefits and uncertainties, and accountability for follow-up. An analytical report does not carry out those tasks.

Peppy’s shipping policy describes intake review by a licensed provider and prescription fulfillment through a licensed compounding pharmacy when treatment is approved. That pathway does not guarantee access to GHK-Cu or any other compound mentioned in a research report. A patient should ask what the clinician actually recommends and why, without treating a research listing as a menu of promised prescriptions.

Record missing information as unknown rather than assuming it is favorable or unfavorable. For this Amino USA comparison, that includes the full report, current storefront details, and firsthand product performance. For Peppy, it includes the reader’s own eligibility and any eventual prescribing decision.

Then verify the facts that matter for care. FDA’s pharmacy guidance covers prescriptions, pharmacy licensure, and pharmacist access. Its compounding guidance explains that compounded drugs are not FDA-approved. Neither an inaccessible certificate nor a polished clinical website resolves those product-specific questions. A careful decision separates what a document says, what remains unverified, and what a clinician must assess for the individual.